Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
23 September 2022 - 12:43AM
Business Wire
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the
“Company” or “Appili”), a biopharmaceutical company focused on drug
development for infectious diseases and biodefense, today announced
the results from its annual and special meeting of shareholders
held earlier today.
Based on the proxies received and the vote conducted at the
meeting, all tabled resolutions were approved by the shareholders
of the Company, including the election of the following directors
for the ensuing year: Ian Mortimer, Brian Bloom, Juergen Froehlich,
Theresa Matkovits, Rochelle Stenzler and Armand Balboni.
Voting results for each director are summarized below:
Name of
Nominee
Percentage of Votes For
Percentage of Votes Against
Percentage of Votes Withheld
Ian Mortimer
19,490,794 (98.42%)
307,825 (1.55%)
5,300 (0.03%)
Brian Bloom
16,812,009 (84.89%)
2,985,610 (15.08%)
6,300 (0.03%)
Juergen Froehlich
16,808,009 (84.87%)
2,989,610 (15.10%)
6,300 (0.03%)
Theresa Matkovits
19,489,794 (98.41%)
307,825 (1.55%)
6,300 (0.03%)
Rochelle Stenzler
19,490,794 (98.42%)
307,825 (1.55%)
5,300 (0.03%)
Armand Balboni
16,808,009 (84.87%)
2,989,610 (15.10%)
6,300 (0.03%)
In addition to the election of the directors of the Company as
noted above, the Shareholders:
- re-appointed PricewaterhouseCoopers, LLP, Chartered
Accountants, as the independent auditor of the Company for the
ensuing year and authorized the directors of the Company to fix
their remuneration;
- approved amendments to the Company’s stock option plan to,
inter alia, change the plan from a “fixed plan” to a rolling 10%
plan; and
- approved the Company’s equity incentive plan.
The Company has filed a report of the voting results on all
resolutions voted on the Meeting on the Company’s SEDAR profile at
www.sedar.com
About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical
company that is purposefully built, portfolio-driven, and
people-focused to fulfill its mission of solving life-threatening
infections. By systematically identifying urgent infections with
unmet needs, Appili’s goal is to strategically develop a pipeline
of novel therapies to prevent deaths and improve lives. The Company
is currently advancing a diverse range of anti-infectives,
including, a vaccine candidate to eliminate a serious biological
weapon threat, a topical antiparasitic product for the treatment of
a disfiguring disease, a broad-spectrum antifungal, and two novel
antibiotic programs. Led by a proven management team, Appili is at
the epicenter of the global fight against infection. For more
information, visit www.AppiliTherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220922005885/en/
Media Contact: Danielle
Raabe/APCO Worldwide T: 1-646-717-9915 E:
DRaabe@apcoworldwide.com
Investor Relations Contact:
Armand Balboni, CEO Appili Therapeutics
Info@AppiliTherapeutics.com
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
Von Mär 2023 bis Mär 2024